{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:02:43Z","timestamp":1794535363311,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.amjcard.2013.04.051","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T08:31:38Z","timestamp":1370593898000},"page":"720-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Effectiveness of Spironolactone Plus Ambrisentan for Treatment of\u00a0Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)"],"prefix":"10.1016","volume":"112","author":[{"given":"Bradley A.","family":"Maron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Opotowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Aghamohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Loscalzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2013.04.051_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","article-title":"Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study","volume":"15","author":"Maron","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2013.04.051_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"De Man","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2013.04.051_bib3","first-page":"33","article-title":"[Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension]","volume":"70","author":"Martyniuk","year":"1998","journal-title":"Ter Arkh"},{"key":"10.1016\/j.amjcard.2013.04.051_bib4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cct.2009.04.003","article-title":"Role of vasopressin and aldosterone in pulmonary arterial hypertension: a pilot study","volume":"30","author":"Bansal","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.amjcard.2013.04.051_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-14-91","article-title":"A\u00a0pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial","author":"Elinoff","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.amjcard.2013.04.051_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2013.04.051_bib7","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2013.04.051_bib8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.amjcard.2012.06.040","article-title":"Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan","volume":"110","author":"Shapiro","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib10","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1161\/CIRCULATIONAHA.112.109868","article-title":"GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension","volume":"126","author":"Piao","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2013.04.051_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.111.062927","article-title":"Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension","volume":"126","author":"White","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2013.04.051_bib12","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00300.2012","article-title":"Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension","author":"Preston","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1253\/jcj.46.1095","article-title":"Is captopril effective in primary pulmonary hypertension?","volume":"46","author":"Kokubu","year":"1982","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2013.04.051_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.amjcard.2013.04.051_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.amjcard.2012.01.368","article-title":"Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension","volume":"109","author":"Pui-Sze So","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.healun.2006.12.014","article-title":"Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension","volume":"26","author":"Cabrol","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.amjcard.2013.04.051_bib18","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.amjcard.2012.07.037","article-title":"Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children","volume":"110","author":"Kirshnan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2013.04.051_bib19","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1253\/circj.CJ-11-0473","article-title":"Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disorder","volume":"75","author":"Miyamichi-Yamamoto","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2013.04.051_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.amjcard.2013.04.051_bib21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914913010680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914913010680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:03:03Z","timestamp":1762077783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914913010680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0002914913010680"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2013.04.051","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Spironolactone Plus Ambrisentan for Treatment of\u00a0Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2013.04.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}